Panacea Biotec share news, announcements and annual reports
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹325.90down ₹3.15 (0.96%)BSE ₹326.15
Share price at the NSE close on 29 Oct 2026. Previous close ₹329.05.
29 Oct: open ₹329.00, high ₹331.70, low ₹323.05
52-week range of traded prices to 29 Oct 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,996 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 25,41247.9% delivered
Panacea Biotec share news and announcements
875 announcements, routine notices left out, newest first. Page 18 of 18.
Nov 2007
8 Nov · Issue of Equity shares
Panacea Biotec Ltd. has informed the Exchange vide its letter dated November 07, 2007 that : "The Company has received a Conversion Notice with respect to 80 Zero Coupon Foreign Currency Convertible Bonds (Tranche 2) due on 2011 amounting to US$ 8 Million, from one of the Bondholders namely, Merrill Lynch Capital Markets Espana SA.SV. Accordingly, the Company has allotted 9,87,554 Equity Shares of Re. 1/- each to the above FCCB holder in the meeting of its Share Transfer-cum-investors Grievance Committee of the Board of Directors held on 31st October, 2007."
Oct 2007
23 Oct · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated October 23, 2007, titled "Panacea Biotec reports financial results for the Quarter and Half Year ended September 30, 2007". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated October 10, 2007, titled "Panacea Biotec signs an MoU with Panjab University to develop New Chemical Entities". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Oct · Meeting
Panacea Biotec Ltd. has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 29, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Oct · Board meeting
To inter-alia, consider and take on record the Unaudited Financial Results (Provisional) for the quarter as well as half-year ended September 30, 2007.4 Oct · Business
Panacea Biotec Ltd. has informed the Exchange that: "The Company has entered into a Memorandum of Agreement (MOA) with Family Vaccines, Philippines to provide access to value added combination vaccines under the umbrella of "Easy Vaccines" manufactured by the Company, to the people in Philippines through a chain of 50 immunization clinics, run by Family Vaccines". Further, a copy of a press release in this regard, dated October 04, 2007, titled "Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines in Philippines" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
25 Sep · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated September 25, 2007, titled "Panacea Biotec inaugurates Vaccine Formulation Plant (VFP) on their Annual Day at Baddi, unveils its new Corporate Identity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Sep · Limited Review Report
Panacea Biotec Ltd. has informed the Exchange that the auditors have conducted the limited review of the un-audited financial results for the quarter ended June 30, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Dividend
Panacea Biotec Ltd. had informed the Exchange that the Board had recommended dividend at the rate of 100% (i.e. Re. 1 per Equity share of Re. 1 each) on the Equity Share Capital of the Company in their meeting held on July 24,2007. The company has now informed the Exchange that the said dividend, if declared at the forthcoming Annual General Meeting, will be paid on or before October 28,2007. Further, the dividend on the Equity Shares, if approved, will absorb an amount of Rs.65,855,192/-.
Jul 2007
25 Jul · Meeting
Panacea Biotec Ltd. has informed the Exchange that the Company's Register of Members and Share Transfer Books shall remain closed from September 25, 2007 to September 29, 2007 (both days inclusive) for ascertaining the entitlement to receive dividend, if any, declared by the Shareholders in the ensuing Annual General Meeting scheduled to be held on September 29, 2007.24 Jul · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated July 24, 2007, titled "Panacea Biotec reports consistent financial results for the Quarter ended June 30, 2007". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Jul · Board meeting
Meeting on 24 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
28 Jun · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated June 28, 2007, titled "Panacea Biotec forays into Cancer treatment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jun · Utilisation of Funds
Panacea Biotec Ltd. has informed the Exchange with respect to the Board Meeting held on June 14, 2007 that, out of US$100 Million Foreign Currency Convertible Bonds (FCCBs) issued during February, 2006, 8,604,904 Equity Shares issued during the year upon conversion of FCCBs worth US$ 55 million. Further, subsequent to March 2007, 24,688 Equity Shares were issued upon conversion of FCCBs aggregating US$ 200,000. Out of the net proceeds of Bonds issue, an amount of Rs.4,297.64 million has been utilised till March 31, 2007 as under: Capital Expenditure - Rs.1,495.70 million, Investment in Cambridge Biostability Ltd., U.K. - Rs.168.07 million, Repayment of Foreign Currency Loan - Rs.14.61 million, Used for payment of Loan and general corporate purposes - Rs.2,483.09 million and issue expenses - Rs.136.17 million. Further, pending utilisation, an amount of Rs.173.84 million (US$4 million) was lying in the Bank Account abroad as per FEMA Guidelines.14 Jun · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated June 14, 2007, titled "Panacea Biotec reports 140.9% rise in net profit For financial year ended March 31, 2007 Net Turnover up by 55.0%. EBIDTA surges by 86.3%". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jun · Dividend
Panacea Biotec Ltd. has informed the Exchange that the Board of Directors of the Company held on June 14, 2007 has recommended dividend @ 100% (i.e. Re.1/- per Share) on Equity Shares of the Company, for the financial year 2006-07.5 Jun · Remuneration
Panacea Biotec Ltd. has submitted to the Exchange a copy of the Abstract of the terms and conditions of the revision in terms of remuneration of Mr. Soshil kumar Jain, Chairman, Mr. Ravinder Jain, Managing Director, Mr. Rajesh Jain, Joint Managing Director, Mr. Sandeep Jain, Joint Managing Director and Mr. Sumit Jain, Director (Operations & Projects) of the Company pursuant to Section 302 of the Companies Act, 1956. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
31 May · Board meeting
To interalia, consider and approve the Audited Financial Results for the Financial year 2006-2007 and to recommend dividend, if any, on the Share Capital of the Company.17 May · Conversion of FCCBs
Panacea Biotec Ltd. had informed the Exchange regarding allotment of 4914592 shares pursuant to conversion notices received for 269 bonds (Tranche 1) and 50 bonds (Tranche 2). The company has now informed the Exchange that Company have received conversion notice from one bondholder in respect of 2 bonds (Tranche 2). Accordingly, the Share transfer cum Investor's Grievances Committee of the Company at its meeting held on today i.e. May 17, 2007 has allotted 24688 Equity Shares of the Company to the Bond holder.
Apr 2007
11 Apr · Results
Panacea Biotec Ltd. has informed the Exchange that: "The Company will be publishing the Audited Results for the Financial Year ended 31st March, 2007 within three months period i.e. upto 30th June, 2007 and the Unaudited Financial Results for the last quarter of the Financial Year (i.e. quarter ended on 31st March, 2007) will not be published".10 Apr · E-mail ID for Investor Complaints
Panacea Biotec Ltd. has informed the Exchange that "Company has generated an exclusive e-mail ID investorgrievances@panaceabiotec.com for registering Queries/Complaints/Grievances by investors. The said e-mail ID has been hosted on the Company's website i.e. www.panaceabiotec.com under the head "Contact Us".
Feb 2007
20 Feb · Results
Panacea Biotec Ltd. has informed the Exchange that: "The result for the resolution passed by postal ballot has been announced by the Chairman today (February 16,2007)". Further, a copy of the Result of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
18 Jan · Business
Panacea Biotec Ltd. has informed the Exchange regarding a press release dated January 18, 2007, titled "Panacea Biotec reports Excellent Financial Results for Quarter & Nine Months Ended December 31, 2006-Turnover up by 79% & Net profit surges by 422% in Q3". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jan · Meeting
Panacea Biotec Ltd. has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001 that the following resolutions are proposed to be passed by the shareholders of the Company by way of a Postal Ballot: 1) Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 authorising the Board of Directors to mortgage and/or charge any of its movable and/or immovable properties or the whole or substantially the whole of an undertaking or undertakings of the Company. 2) Special Resolution for Alteration in the Articles of Association by way of substitution of Article 2. 3) Special Resolution for Alteration in the Articles of Association by way of substitution of Article 143. The duly completed postal ballot form should reach the scrutinizer before the close of working hours, on or before February 09, 2007. The Company has appointed Mr. Umesh Singhal of M/s. U.S. & Associates, Company Secretaries, as Scrutinizer to scrutinize the Postal Ballot in a fair and transparent manner. The result of the postal ballot will be announced by the Chairman on February 16, 2007. A copy of the Postal Ballot Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Jan · Board meeting
To inter-alia, consider and take on record the Unaudited Financial Results (Provisional) for the quarter and nine months ended 31st December, 2006.